|
1
|
Hoehner JC, Gestblom C, Hedborg F,
Sandstedt B, Olsen L and Påhlman S: A developmental model of
neuroblastoma: Differentiating stroma-poor tumors' progress along
an extra-adrenal chromaffin lineage. Lab Invest. 75:659–675.
1996.PubMed/NCBI
|
|
2
|
Spix C, Pastore G, Sankila R, Stiller CA
and Steliarova-Foucher E: Neuroblastoma incidence and survival in
European children (1978–1997): Report from the automated childhood
cancer information system project. Eur J Cancer. 42:2081–2091.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Izbicki T, Mazur J and Izbicka E:
Epidemiology and etiology of neuroblastoma: An overview. Anticancer
Res. 23:755–760. 2003.PubMed/NCBI
|
|
4
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Bernardi B, Mosseri V, Rubie H, Castel
V, Foot A, Ladenstein R, Laureys G, Beck-Popovic M, de Lacerda AF,
Pearson AD, et al: Treatment of localised resectable neuroblastoma.
Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.
Br J Cancer. 99:1027–1033. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zage PE, Kletzel M, Murray K, Marcus R,
Castleberry R, Zhang Y, London WB and Kretschmar C; Children's
Oncology Group, : Outcomes of the POG 9340/9341/9342 trials for
children with high-risk neuroblastoma: A report from the children's
oncology group. Pediatr Blood Cancer. 51:747–753. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hoy SM: Dinutuximab: A review in high-risk
neuroblastoma. Target Oncol. 11:247–253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bai X, Cerimele F, Ushio-Fukai M, Waqas M,
Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, et
al: Honokiol, a small molecular weight natural product, inhibits
angiogenesis in vitro and tumor growth in vivo. J Biol Chem.
278:35501–35507. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen XR, Lu R, Dan HX, Liao G, Zhou M, Li
XY and Ji N: Honokiol: A promising small molecular weight natural
agent for the growth inhibition of oral squamous cell carcinoma
cells. Int J Oral Sci. 3:34–42. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X, Duan X, Yang G, Zhang X, Deng L,
Zheng H, Deng C, Wen J, Wang N, Peng C, et al: Honokiol crosses BBB
and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral
gliosarcoma model and human U251 xenograft glioma model. PLoS One.
6:e184902011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shigemura K, Arbiser JL, Sun SY, Zayzafoon
M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhau HE and Chung
LW: Honokiol, a natural plant product, inhibits the bone metastatic
growth of human prostate cancer cells. Cancer. 109:1279–1289. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prasad R, Kappes JC and Katiyar SK:
Inhibition of NADPH oxidase 1 activity and blocking the binding of
cytosolic and membrane-bound proteins by honokiol inhibit migratory
potential of melanoma cells. Oncotarget. 7:7899–7912. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin JW, Chen JT, Hong CY, Lin YL, Wang KT,
Yao CJ, Lai GM and Chen RM: Honokiol traverses the blood-brain
barrier and induces apoptosis of neuroblastoma cells via an
intrinsic bax-mitochondrion-cytochrome c-caspase protease pathway.
Neuro Oncol. 14:302–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Proskuryakov SY, Konoplyannikov AG and
Gabai VL: Necrosis: A specific form of programmed cell death? Exp
Cell Res. 283:1–16. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moriwaki K and Chan FK: RIP3: A molecular
switch for necrosis and inflammation. Genes Dev. 27:1640–1649.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai R, Xue W, Liu S, Petersen RB, Huang K
and Zheng L: Overexpression of glyceraldehyde 3-phosphate
dehydrogenase prevents neurovascular degeneration after retinal
injury. FASEB J. 29:2749–2758. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin CJ, Chang YA, Lin YL, Liu SH, Chang CK
and Chen RM: Preclinical effects of honokiol on treating
glioblastoma multiforme via G1 phase arrest and cell apoptosis.
Phytomedicine. 23:517–527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin CJ, Chen TL, Tseng YY, Wu GJ, Hsieh
MH, Lin YW and Chen RM: Honokiol induces autophagic cell death in
malignant glioma through reactive oxygen species-mediated
regulation of the p53/PI3K/Akt/mTOR signaling pathway. Toxicol Appl
Pharmacol. 304:59–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hahm ER, Sakao K and Singh SV: Honokiol
activates reactive oxygen species-mediated cytoprotective autophagy
in human prostate cancer cells. Prostate. 74:1209–1221. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang M, Harashima N, Moritani T, Huang W
and Harada M: The roles of ROS and caspases in TRAIL-induced
apoptosis and necroptosis in human pancreatic cancer cells. PLoS
One. 10:e01273862015. View Article : Google Scholar : PubMed/NCBI
|
